Roman Rothaermel

VC Principal @ SCI Ventures | Neuro-regeneration & modulation | Therapeutics & devices

Co-founder

Mable· Summer 2021 🇬🇧 London, England, United Kingdom

in LinkedIn

2024Principal· SCI Ventures

Founder · since 2019

Company

SCI Ventures

Role

Principal

current

Stage

—

no public source

Raised

—

no public source

Based

London Area, United Kingdom

current

Founder / co-founder — the company's markEmployee / research role

Source: LinkedIn work history

Profile coverage5 of 7 · missing posts, contact

Mable

First personalized migraine clinic using genetics and telehealth.

Summer 2021

Experience

Career

SCI Ventures
Principal · London Area, United Kingdom · 2024 – Present
2024
Kesmalea Therapeutics
Director Corporate Strategy · 2023 – 2024
2023
mable | Neurolytic Healthcare
Co-founder
Co-Founder & CEO at mable | Neurolytic Healthcare · Greater London, England, United Kingdom · 2019 – 2023
2019
University of Oxford
PhD Neuroscience · 2017 – 2021
2017
University of Oxford
Masters Student · Greater Oxford Area · 2016 – 2017
2016
Balliol College, University of Oxford
Graduate Student President · Oxford, United Kingdom · 2018 – 2019
2018
University of Oxford
Masters Research Student · Oxford, United Kingdom · 2014 – 2015
2014
University of Bristol
Postgraduate researcher in Neuropharmacology · Bristol, United Kingdom · 2014 – 2015
2014
Max Planck Institute of Psychiatry
Undergraduate Student Researcher · Munich Area, Germany · 2013
2013

Bio

Roman is a neuroscientist who has conducted several years of research on memory encoding in the brain, neuropharmacology and drug target characterization. During his PhD at Oxford University he uncovered a new mechanism causing brain-wide synchronization which is necessary for correct retrieval of complex memories. He also has an MSc in Neuroscience (Oxford, UK) and MSc in Biology (Tubingen, Germany).